河南羚锐制药股份有限公司2025年半年度报告摘要

Section 1: Important Notes - The semi-annual report summary is derived from the full semi-annual report, and investors are encouraged to read the complete report for a comprehensive understanding of the company's operational results, financial status, and future development plans [1][1][1] - The company's board of directors, supervisory board, and senior management guarantee the authenticity, accuracy, and completeness of the semi-annual report, and they bear individual and joint legal responsibility for any false records, misleading statements, or significant omissions [1][1][1] - All directors attended the board meeting [1] - The semi-annual report has not been audited [1] - There are no profit distribution plans or capital reserve conversion plans approved by the board during the reporting period [1] Section 2: Company Overview - Company profile and basic information are provided [2][2] - Key financial data is presented in RMB [2][2] - The top 10 shareholders' shareholding situation is detailed [2][2] - There are no applicable details regarding preferred shareholders or changes in controlling shareholders [2][2] - There are no applicable details regarding the existence of bonds as of the report approval date [2][2] Section 3: Important Matters - The company is required to disclose significant changes in operational conditions during the reporting period, as well as any matters that have had or are expected to have a significant impact on the company's operations [3][3]